S&P 500 6,976.44 ▲ 37.41 (+0.54%)
DOW 49,407.66 ▲ 515.19 (+1.05%)
NASDAQ 23,592.11 ▲ 130.29 (+0.56%)
US Markets Closed

YDES

YD Bio Ltd

Price Chart
Latest Quote

$11.47

Current Price
Previous Close $11.87
Open $11.65
Day High $12.00
Day Low $11.30
Volume 26,974
Fetched: 2026-02-03T04:43:16
Stock Information
Shares Outstanding 70.52M
Total Debt $22K
Cash Equivalents $3.13M
Revenue $510K
Net Income $-1.41M
Sector Healthcare
Industry Biotechnology
Market Cap $808.88M
EPS (TTM) $-0.02
Exchange NGM
🌐 Visit Website
📊 Custom Metrics & Score
Score: 22/42
Debt to Equity 0.00
Debt to Earnings 0.15
Current Ratio 13.18
Quick Ratio 12.91
Avg Revenue Growth 22.88%
Profit Margin -276.58%
Return on Equity -21.42%
Avg FCF Growth 4193.13%
FCF Yield -0.59%
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
Date Close Volume
2026-02-02 $11.47 26,974
2026-01-30 $11.87 35,000
2026-01-29 $11.03 58,200
2026-01-28 $12.24 13,300
2026-01-27 $12.16 33,400
2026-01-26 $12.02 18,100
2026-01-23 $12.36 11,800
2026-01-22 $12.30 62,000
2026-01-21 $12.00 53,100
2026-01-20 $11.95 80,000
2026-01-16 $11.32 28,600
2026-01-15 $11.42 94,600
2026-01-14 $11.80 13,100
2026-01-13 $11.82 17,300
2026-01-12 $11.82 52,800
2026-01-09 $12.34 58,700
2026-01-08 $12.33 116,300
2026-01-07 $11.50 115,700
2026-01-06 $11.66 328,700
2026-01-05 $12.68 70,500
About YD Bio Ltd

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

Income Statement (Annual)
Revenue
Metric 2024-12-31 2023-12-31
Reconciled Cost Of Revenue $355,004 $196,686
Cost Of Revenue $355,004 $196,686
Total Revenue $510,360 $350,131
Operating Revenue $510,360 $350,131
Expenses
Metric 2024-12-31 2023-12-31
Interest Expense $772 $2,144
Total Expenses $1,972,783 $357,247
Other Income Expense $64,908 $26,620
Other Non Operating Income Expenses $64,415 $29,351
Net Non Operating Interest Income Expense $11,036 $-1,854
Interest Expense Non Operating $772 $2,144
Operating Expense $1,617,779 $160,561
Selling And Marketing Expense $1,957 $7,492
General And Administrative Expense $1,124,469 $153,069
Income & Earnings
Metric 2024-12-31 2023-12-31
Net Income From Continuing Operation Net Minority Interest $-1,411,559 $13,560
Net Interest Income $11,036 $-1,854
Interest Income $11,808 $290
Normalized Income $-1,411,953 $15,658
Net Income From Continuing And Discontinued Operation $-1,411,559 $13,560
Total Operating Income As Reported $-1,461,930 $-9,847
Net Income Common Stockholders $-1,411,559 $13,560
Net Income $-1,411,559 $13,560
Net Income Including Noncontrolling Interests $-1,411,559 $13,560
Net Income Continuous Operations $-1,411,559 $13,560
Pretax Income $-1,386,479 $17,650
Special Income Charges $493 $-2,731
Interest Income Non Operating $11,808 $290
Operating Income $-1,462,423 $-7,116
Gross Profit $155,356 $153,445
Per Share Metrics
Metric 2024-12-31 2023-12-31
Diluted EPS - $0.00
Basic EPS - $0.00
Other
Metric 2024-12-31 2023-12-31
Tax Effect Of Unusual Items $99 $-633
Tax Rate For Calcs $0 $0
Normalized EBITDA (Bullshit earnings) $-1,281,465 $24,977
Total Unusual Items $493 $-2,731
Total Unusual Items Excluding Goodwill $493 $-2,731
Reconciled Depreciation $104,735 $2,452
EBITDA (Bullshit earnings) $-1,280,972 $22,246
EBIT $-1,385,707 $19,794
Diluted NI Availto Com Stockholders $-1,411,559 $13,560
Tax Provision $25,080 $4,090
Write Off $-493 $2,731
Research And Development $491,353 $0
Selling General And Administration $1,126,426 $160,561
Other Gand A $1,124,469 $153,069
Diluted Average Shares - $70,095,411
Basic Average Shares - $70,095,411
Fetched: 2026-02-02
Balance Sheet (Annual)
Assets
Metric 2024-12-31 2023-12-31
Net Tangible Assets $3,910,211 $22,994
Total Assets $6,864,226 $321,212
Total Non Current Assets $3,396,344 $49,488
Non Current Deferred Assets $628,232 $24,565
Non Current Deferred Taxes Assets $0 $24,565
Investmentin Financial Assets $0 $10,618
Goodwill And Other Intangible Assets $2,680,035 $0
Other Intangible Assets $2,680,035 -
Current Assets $3,467,882 $271,724
Prepaid Assets $35,453 $16,788
Inventory $37,335 $69,404
Receivables $262,796 $98,434
Taxes Receivable $159,287 $267
Notes Receivable $16,927 $0
Accounts Receivable $86,582 $98,167
Allowance For Doubtful Accounts Receivable $-3,055 $-3,769
Gross Accounts Receivable $89,637 $101,936
Cash Cash Equivalents And Short Term Investments $3,132,298 $87,098
Cash And Cash Equivalents $3,132,298 $87,098
Debt
Metric 2024-12-31 2023-12-31
Total Debt $22,555 $47,576
Long Term Debt And Capital Lease Obligation $5,684 $0
Current Debt And Capital Lease Obligation $16,871 $47,576
Current Debt $290 $34,319
Other Current Borrowings - $34,319
Liabilities
Metric 2024-12-31 2023-12-31
Total Liabilities Net Minority Interest $273,980 $298,218
Total Non Current Liabilities Net Minority Interest $10,920 $0
Other Non Current Liabilities $3,773 -
Non Current Deferred Liabilities $1,463 -
Non Current Deferred Taxes Liabilities $1,463 -
Current Liabilities $263,060 $298,218
Current Notes Payable $290 $0
Payables And Accrued Expenses $246,189 $250,298
Payables $63,829 $237,196
Accounts Payable $26,743 $17,976
Current Deferred Liabilities - $344
Total Tax Payable - $1,969
Equity
Metric 2024-12-31 2023-12-31
Common Stock Equity $6,590,246 $22,994
Total Equity Gross Minority Interest $6,590,246 $22,994
Stockholders Equity $6,590,246 $22,994
Gains Losses Not Affecting Retained Earnings $45,072 $47,211
Retained Earnings $-1,927,043 $-515,484
Other
Metric 2024-12-31 2023-12-31
Ordinary Shares Number $70,095,411 $70,095,411
Share Issued $70,095,411 $70,095,411
Tangible Book Value $3,910,211 $22,994
Invested Capital $6,590,536 $57,313
Working Capital $3,204,822 $-26,494
Capital Lease Obligations $22,265 $13,257
Total Capitalization $6,590,246 $22,994
Additional Paid In Capital $8,328,040 $386,067
Capital Stock $144,177 $105,200
Common Stock $144,177 $105,200
Long Term Capital Lease Obligation $5,684 $0
Current Capital Lease Obligation $16,581 $13,257
Current Accrued Expenses $182,360 $13,102
Dueto Related Parties Current $37,086 $217,251
Investments And Advances $0 $10,618
Net PPE $88,077 $14,305
Accumulated Depreciation $-17,431 $-7,949
Gross PPE $105,508 $22,254
Machinery Furniture Equipment $81,810 $9,139
Buildings And Improvements $23,698 $13,115
Properties $0 $0
Finished Goods $37,335 $69,404
Current Deferred Revenue - $0
Available For Sale Securities - $10,618
Fetched: 2026-02-02
Cash Flow Statement (Annual)
Free Cash Flow
Metric 2024-12-31 2023-12-31
Free Cash Flow $-4,747,812 $-55,947
Operating Activities
Metric 2024-12-31 2023-12-31
Operating Cash Flow $-1,836,818 $-55,657
Cash Flow From Continuing Operating Activities $-1,836,818 $-55,657
Operating Gains Losses - $466
Investing Activities
Metric 2024-12-31 2023-12-31
Capital Expenditure $-2,910,994 $-290
Investing Cash Flow $-2,900,670 $-290
Cash Flow From Continuing Investing Activities $-2,900,670 $-290
Financing Activities
Metric 2024-12-31 2023-12-31
Issuance Of Capital Stock $7,860,181 $52,952
Financing Cash Flow $7,727,646 $113,887
Cash Flow From Continuing Financing Activities $7,727,646 $113,887
Net Other Financing Charges $-99,558 $93,544
Net Common Stock Issuance $7,860,181 $52,952
Common Stock Issuance $7,860,181 $52,952
Other
Metric 2024-12-31 2023-12-31
Repayment Of Debt $-32,977 $-32,609
Interest Paid Supplemental Data $772 $2,144
Income Tax Paid Supplemental Data $0 $0
End Cash Position $3,132,298 $87,098
Beginning Cash Position $87,098 $30,142
Effect Of Exchange Rate Changes $55,042 $-984
Changes In Cash $2,990,158 $57,940
Net Issuance Payments Of Debt $-32,977 $-32,609
Net Long Term Debt Issuance $-32,977 $-32,609
Long Term Debt Payments $-32,977 $-32,609
Net Investment Purchase And Sale $10,324 $0
Sale Of Investment $10,324 $0
Net Intangibles Purchase And Sale $-2,836,080 $0
Purchase Of Intangibles $-2,836,080 $0
Net PPE Purchase And Sale $-74,914 $-290
Purchase Of PPE $-74,914 $-290
Change In Working Capital $-567,808 $-126,696
Change In Other Working Capital $-614,137 -
Change In Other Current Liabilities $-12,239 $-47,082
Change In Payables And Accrued Expense $223,791 $9,996
Change In Accrued Expense $213,595 $4,605
Change In Payable $10,196 $5,391
Change In Account Payable $10,196 $5,391
Change In Prepaid Assets $-182,721 $4,818
Change In Inventory $28,517 $-30,570
Change In Receivables $-11,019 $-63,858
Changes In Account Receivables $6,297 $-63,858
Other Non Cash Items $11,731 $47,740
Asset Impairment Charge $-493 $2,731
Deferred Tax $26,576 $4,090
Deferred Income Tax $26,576 $4,090
Depreciation Amortization Depletion $104,735 $2,452
Depreciation And Amortization $104,735 $2,452
Amortization Cash Flow $94,536 $0
Amortization Of Intangibles $94,536 $0
Depreciation $10,199 $2,452
Gain Loss On Sale Of PPE $0 $466
Net Income From Continuing Operations $-1,411,559 $13,560
Fetched: 2026-02-02